Kirkland & Ellis LLP

04/23/2026 | Press release | Distributed by Public on 04/23/2026 11:41

Kirkland Advises Apotex on Strategic Transaction with Cumberland Pharmaceuticals to Integrate their U.S. Branded Businesses

Kirkland & Ellis advised Apotex, the largest Canadian based pharmaceutical company, on a strategic transaction with Cumberland Pharmaceuticals Inc., a U.S. based specialty pharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex. Under the terms of the agreement, Apotex will add a portfolio of branded medicines to its U.S. business. The transaction is expected to significantly expand Apotex's U.S. specialty and hospital focused business with a diversified basket of products across acute care, oncology, infectious disease and gastroenterology.

Read the transaction press release

The Kirkland team included corporate lawyers Ngozi Nezianya, Matt Arenson, Matt Schoener and Jacob Groppel; and technology and IP transactions lawyers Aaron Lorber, Matt Darch, Michelle Kelrikh and Sarah Alpert.

Kirkland & Ellis LLP published this content on April 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 23, 2026 at 17:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]